Major Investments in Pharmaceutical Sector to Boost Mexican Economy
Augusto Muench, the General Director of pharmaceutical company Boehringer Ingelheim México, announced a multi-annual investment of 3,500 million pesos to transform their tablet production plant in Xochimilco into the world’s largest, surpassing existing Boehringer Ingelheim sites in Spain, China, Japan, Greece, and Germany.
Supplying Local Market and Exporting to 40 Countries
Muench stated during Thursday’s morning conference with Mexico City Mayor Claudia Sheinbaum, “From Xochimilco, south of Mexico City, we will supply the local market with antihypertensive and antidiabetic drugs while exporting to 40 countries across all continents.”
Creating Over 1,800 Direct Jobs and Indirectly Supporting Thousands More
This investment will create 1,800 direct jobs, along with approximately 15,000 indirect jobs. The production target is 5,000 million tablets per year. Boehringer Ingelheim has been dedicated to human and animal health through medical therapy innovation for over 70 years in Mexico.
AstraZeneca’s Expansion Plans
Julio Ordaz, AstraZeneca’s General Director, announced an investment of 2,250 million pesos between 2024 and 2026, with 460 million already executed. This will generate over 600 specialized jobs and more than 6,500 indirect jobs, benefiting the Mexico City, State of Mexico, and Jalisco regions.
Plan México
Ordaz emphasized, “Today we reaffirm our commitment to Plan México through an investment divided into three specific segments…”
- More than 1,400 million pesos for clinical research, ensuring development in institutions like the National Autonomous University of Mexico (UNAM), the Polytechnic Institute of National (IPN), and the Mexican Social Security Institute (IMSS).
- Expansion of the Innovation and Technology Center, providing services in information technology, digital services, artificial intelligence, human resources, and finance.
- Expansion of the manufacturing site in the State of Mexico, producing essential medications for diabetes type 2 and chronic kidney disease. The plant currently manufactures over 40 million packages, exported to various Latin American countries.
Bayer’s Modernization Investment
Bayer will invest 3,000 million pesos in modernizing its 14 plants in Veracruz, the State of Mexico, and Tlaxcala. These resources will update their active pharmaceutical ingredients (APIs) plant, develop a new line of sterile hormonal injectables, and expand fungicide biological production.
Carnot Laboratories’ New Farmaceutical Complex
Carnot Laboratories is constructing a pharmaceutical complex in Hidalgo with a 3,500 million pesos investment over the next five years. This will generate 600 highly specialized jobs and incorporate cutting-edge technology for medication production in various presentations, focusing on gastroenterology, women’s health, and cardiovascular diseases for 30 international markets.
Job Creation Estimates
Authorities estimate that these projects will create more than 3,000 direct jobs and approximately 22,000 indirect jobs in the coming years.
Key Questions and Answers
- Who are the companies making these investments? Boehringer Ingelheim, AstraZeneca, Bayer, and Carnot Laboratories.
- What will these investments achieve? Boehringer Ingelheim’s plant in Xochimilco will become the world’s largest, AstraZeneca will expand its operations, Bayer will modernize its plants, and Carnot Laboratories will build a new complex.
- How many jobs will these investments create? Over 3,000 direct jobs and approximately 22,000 indirect jobs are expected.
- What types of medications will these plants produce? The companies will manufacture antihypertensive and antidiabetic drugs, sterile hormonal injectables, fungicides, and medications for gastroenterology, women’s health, and cardiovascular diseases.
- Which regions will benefit from these investments? The projects will significantly impact Mexico City, the State of Mexico, Jalisco, Veracruz, Tlaxcala, and Hidalgo.
